Search Results
Showing 2 of 2 search results for:
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status
Condition
Lymphoma, Non-Hodgkin
Phase
INTERVENTION
Drug: CC-99282, Drug: Obinutuzumab
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 1 of 2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)
Status
Condition
Lymphoma, Non-Hodgkin
Phase
INTERVENTION
Drug: CC-99282, Drug: rituximab
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 2 of 2